BioSpace News Archive

Theralase® Technologies Inc. is pleased to announce that in preclinical research, it’s lead compound, RuvidarTM, when combined with Bacillus Calmette-Guérin, was able to create a new compound with new synergistic characteristics.

BridgeBio Pharma, Inc. announced that on June 6, 2024, the compensation committee of BridgeBio’s board of directors approved equity grants to 18 new employees in restricted stock units for an aggregate of 90,591 shares of the Company’s common stock.

AOP Orphan Pharmaceuticals GmbH continues a successful clinical research program in hematology/oncology with two abstracts accepted for presentation at the European Hematology Association 2024 hybrid congress in Madrid, Spain.

Revive Therapeutics Ltd. announced today an update on the meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) of the Revive LC POC Lateral Flow Test Kit (the “Product”) for feedback on the classification, development and regulatory submission strategy for a point-of-care in vitro diagnostic device that aids in the detection of post COVID-19 conditions.

Eilean Therapeutics LLC, is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the IND for lomonitinib (ZE46-0134), allowing the company to proceed with a Phase 1 clinical trial in FLT3 mutated relapsed/refractory (R/R) AML.

Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a/b trial of its long-acting herpes simplex virus (HSV) helicase-primase inhibitor candidate ABI-5366.6

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) today announced it will release preliminary results from the first five “lead-in” patients in the Company’s ongoing proof-of-concept (PoC) human clinical trial evaluating the safety and effectiveness of delivering transvascular energy to ablate relevant problematic nerves and mitigate pain in patients with pancreatic cancer pain on Tuesday, June 18, 2024.

Veru Inc. announced that the Company will present two presentations at the American Diabetes Association’s 84th Scientific Sessions, taking place June 21-24, 2024, in Orlando, Florida.

Surrozen, Inc. presented a poster on the preliminary results of a Phase 1a study of SZN-043, a novel R-Spondin mimetic, in healthy volunteers and subjects with liver cirrhosis on June 8, 2024 at the 2024 European Association for the Study of the Liver in Milan.

RenovoRx, Inc. announced that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships.